Martin Carré

1.1k total citations · 1 hit paper
32 papers, 443 citations indexed

About

Martin Carré is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Martin Carré has authored 32 papers receiving a total of 443 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Hematology, 8 papers in Oncology and 7 papers in Molecular Biology. Recurrent topics in Martin Carré's work include Acute Myeloid Leukemia Research (16 papers), Hematopoietic Stem Cell Transplantation (7 papers) and Chronic Myeloid Leukemia Treatments (5 papers). Martin Carré is often cited by papers focused on Acute Myeloid Leukemia Research (16 papers), Hematopoietic Stem Cell Transplantation (7 papers) and Chronic Myeloid Leukemia Treatments (5 papers). Martin Carré collaborates with scholars based in France, United States and Switzerland. Martin Carré's co-authors include Jean‐Christophe Ianotto, Franck E. Nicolini, Delphine Réa, Martine Gardembas, Agnès Guerci‐Bresler, Françoise Rigal‐Huguet, Michel Tulliez, Bruno Villemagne, Marie‐Pierre Noël and François‐Xavier Mahon and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Martin Carré

26 papers receiving 433 citations

Hit Papers

1 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia

2016 315 citations Martin Carré et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Martin Carré France	8	341	249	130	111	45	32	443
Luis Felipe Casado Spain	10	367 1.1×	271 1.1×	136 1.0×	88 0.8×	37 0.8×	23	488
Perttu Koskenvesa Finland	12	366 1.1×	291 1.2×	129 1.0×	112 1.0×	48 1.1×	29	461
Tapan Saikia India	10	176 0.5×	126 0.5×	51 0.4×	77 0.7×	32 0.7×	32	311
William Wierda United States	8	424 1.2×	359 1.4×	187 1.4×	90 0.8×	39 0.9×	11	599
Marie‐Pierre Noël France	10	712 2.1×	612 2.5×	314 2.4×	163 1.5×	50 1.1×	15	786
Mona Lisa Alattar United States	6	378 1.1×	191 0.8×	53 0.4×	78 0.7×	169 3.8×	13	487
Richard Pilot United States	5	177 0.5×	68 0.3×	93 0.7×	164 1.5×	64 1.4×	10	368
A Granda Spain	9	397 1.2×	113 0.5×	49 0.4×	159 1.4×	98 2.2×	11	447
Kristen Pettit United States	12	320 0.9×	187 0.8×	56 0.4×	71 0.6×	221 4.9×	66	550
Senaka Peter United States	7	104 0.3×	77 0.3×	52 0.4×	87 0.8×	40 0.9×	17	308

Countries citing papers authored by Martin Carré

Since Specialization

Citations

This map shows the geographic impact of Martin Carré's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martin Carré with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martin Carré more than expected).

Fields of papers citing papers by Martin Carré

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Martin Carré. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martin Carré. The network helps show where Martin Carré may publish in the future.

Co-authorship network of co-authors of Martin Carré

This figure shows the co-authorship network connecting the top 25 collaborators of Martin Carré. A scholar is included among the top collaborators of Martin Carré based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Martin Carré. Martin Carré is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Michonneau, David, Mikko Keränen, Marie Thérèse Rubio, et al.. (2024). Treatment Patterns and Clinical Outcomes of Patients with Moderate to Severe Acute Graft-Versus-Host Disease: A Multicenter Chart Review Study. SHILAP Revista de lepidopterología. 16(2). 283–294. 1 indexed citations

Bertoli, Sarah, Maël Heiblig, Thibaut Leguay, et al.. (2024). Real-World Multicenter Comparison of Venetoclax and Azacitidine Versus Intermediate or High Dose Cytarabine-Based Salvage for Patients with AML in First Relapse after Front Line Intensive Chemotherapy. a Dataml-IPC-Auraml Consortium Study. Blood. 144(Supplement 1). 4275–4275.

Tavernier, Emmanuelle, Jérôme Cornillon, Martin Carré, et al.. (2024). Azacitidine and Venetoclax As a Salvage Therapy for Relapse after Allogeneic Transplantation for Acute Myeloid Leukemia : A Multicentric Study from French Auraml Group. Blood. 144(Supplement 1). 1518–1518. 2 indexed citations

Orvain, Corentin, Sarah Bertoli, Pierre Péterlin, et al.. (2024). Molecular relapse after first-line intensive therapy in patients with CBF or NPM1-mutated acute myeloid leukemia – a FILO study. Leukemia. 38(9). 1949–1957. 8 indexed citations

Contejean, Adrien, Pierre Chauvelot, Martin Carré, et al.. (2024). Infectious Complications Among Patients Treated with Azacitidine and Venetoclax for Acute Myeloid Leukemia: A Multicentric Real-Life Analysis of the French Auraml Group. Blood. 144(Supplement 1). 1475–1475.

Heiblig, Maël, Emmanuelle Tavernier, Jérôme Cornillon, et al.. (2024). Measurable Residual Disease (MRD) Determinants, Kinetics and Its Impact on Survival in Patients Treated with Azacitidine and Venetoclax for Acute Myeloid Leukemia in Frontline Setting : A Multicentric Study from French Auraml Group. Blood. 144(Supplement 1). 846–846.

Carré, Martin, Emmanuelle Tavernier, Jérôme Cornillon, et al.. (2024). Azacytidine and Venetoclax As a Salvage Therapy in Measurable Residual Disease (MRD) Relapse Post Intensive Chemotherapy or Allogenic Stem Cell Transplantation in Acute Myeloid Leukemia Patients : A Multicentric Study from French Auraml Group. Blood. 144(Supplement 1). 4335–4335. 2 indexed citations

Rennke, Helmut G., Marie Essig, Martin Carré, et al.. (2023). Chronic Myelomonocytic Leukemia Patients With Lysozyme Nephropathy and Renal Infiltration Display Markers of Severe Disease. Kidney International Reports. 8(12). 2733–2741. 2 indexed citations

Garciaz, Sylvain, Sarah Bertoli, David A. Sallman, et al.. (2023). Acute Myeloid Leukemia Patients Who Stopped Venetoclax or/and Azacytidine for Other Reasons Than Progression Have a Prolonged Treatment Free Remission and Overall Survival. a Filo Study. Blood. 142(Supplement 1). 161–161. 7 indexed citations

10.

Orvain, Corentin, Sarah Bertoli, Pierre Péterlin, et al.. (2023). Molecular Relapse after First-Line Intensive Therapy in Patients with Core-Binding Factor and NPM1-Mutated Acute Myeloid Leukemia - a Filo Study. Blood. 142(Supplement 1). 421–421.

11.

Cluzeau, Thomas, Marie Sébert, Michaël Loschi, et al.. (2023). Phase I/II Clinical Trial Evaluating Azacitidine + Venetoclax + Donor Lymphocyte Infusion in Post-Transplant Relapse Myelodysplastic Syndromes and Acute Myeloid Leukemia: Preliminary Results of Ventograft, a GFM Study. Blood. 142(Supplement 1). 3246–3246. 1 indexed citations

12.

Garciaz, Sylvain, Justine Decroocq, Sarah Bertoli, et al.. (2022). Long-Term Survival of Acute Myeloid Leukemia Responding Patients Who Stopped Azacytidine and/or Venetoclax Because of Poor Tolerance or Physician Choice: A Retrospective Multicenter Study from the French Innovative Leukemia Organization (FILO). Blood. 140(Supplement 1). 6147–6148. 2 indexed citations

13.

Gyan, Emmanuel, Arnaud Pigneux, Mathilde Hunault, et al.. (2022). Adjunction of a fish oil emulsion to cytarabine and daunorubicin induction chemotherapy in high-risk AML. Scientific Reports. 12(1). 9748–9748. 2 indexed citations

14.

Cleuziou, Julie, P. Chartier, Martin Carré, et al.. (2021). Total body irradiation using helical tomotherapy: Set-up experience and in-vivo dosimetric evaluation. Cancer/Radiothérapie. 25(3). 213–221. 9 indexed citations

15.

Germi, Raphaële, Sébastien Bailly, Claude‐Eric Bulabois, et al.. (2021). Risk factors of BK viral hemorrhagic cystitis in allogenic hematopoietic stem cell transplantation. Transplant Infectious Disease. 23(5). e13601–e13601. 18 indexed citations

16.

Carré, Martin, et al.. (2020). Agranulocytoses médicamenteuses idiosyncrasiques : analyse de 7 ans dans un hôpital universitaire français. Annales Pharmaceutiques Françaises. 78(3). 230–241. 1 indexed citations

17.

Carré, Martin, et al.. (2018). Maternal adherence to guidance on breast milk collection process. Archives de Pédiatrie. 25(4). 274–279. 11 indexed citations

18.

Carré, Martin, Anne Thiebaut‐Bertrand, Sylvie Larrat, et al.. (2017). Fatal autochthonous fulminant hepatitis E early after allogeneic stem cell transplantation. Bone Marrow Transplantation. 52(4). 643–645. 8 indexed citations

19.

Bulabois, Claude‐Eric, Anne Thiebaut‐Bertrand, Raphaël Itzykson, et al.. (2014). Alemtuzumab for Severe Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation. 20(9). 1451–1454. 13 indexed citations

20.

Carré, Martin, et al.. (1985). [Possible embryofetopathy caused by beta-blocker (sotalol) taken throughout the pregnancy].. PubMed. 40(2). 129–36. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact